CanSino Biologics Inc - Asset Resilience Ratio
CanSino Biologics Inc (CJH) has an Asset Resilience Ratio of 27.47% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CJH liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how CanSino Biologics Inc's Asset Resilience Ratio has changed over time. See CJH book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down CanSino Biologics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CanSino Biologics Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €2.12 Billion | 27.47% |
| Total Liquid Assets | €2.12 Billion | 27.47% |
Asset Resilience Insights
- Very High Liquidity: CanSino Biologics Inc maintains exceptional liquid asset reserves at 27.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
CanSino Biologics Inc Industry Peers by Asset Resilience Ratio
Compare CanSino Biologics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for CanSino Biologics Inc (2016–2024)
The table below shows the annual Asset Resilience Ratio data for CanSino Biologics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.60% | €1.64 Billion ≈ $1.92 Billion |
€7.96 Billion ≈ $9.30 Billion |
-1.65pp |
| 2023-12-31 | 22.25% | €2.07 Billion ≈ $2.42 Billion |
€9.32 Billion ≈ $10.89 Billion |
-0.01pp |
| 2022-12-31 | 22.25% | €2.55 Billion ≈ $2.98 Billion |
€11.47 Billion ≈ $13.41 Billion |
+2.66pp |
| 2021-12-31 | 19.59% | €2.33 Billion ≈ $2.72 Billion |
€11.87 Billion ≈ $13.88 Billion |
+9.71pp |
| 2020-12-31 | 9.88% | €666.64 Million ≈ $779.37 Million |
€6.75 Billion ≈ $7.89 Billion |
-21.07pp |
| 2019-12-31 | 30.95% | €552.34 Million ≈ $645.75 Million |
€1.78 Billion ≈ $2.09 Billion |
+13.36pp |
| 2018-12-31 | 17.59% | €140.00 Million ≈ $163.67 Million |
€795.88 Million ≈ $930.46 Million |
-28.88pp |
| 2017-12-31 | 46.47% | €402.64 Million ≈ $470.72 Million |
€866.36 Million ≈ $1.01 Billion |
+17.66pp |
| 2016-12-31 | 28.82% | €94.00 Million ≈ $109.90 Million |
€326.17 Million ≈ $381.33 Million |
-- |
About CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more